TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05485324

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.

Intervention type: OTHER
Intervention: visual analog scale
Description: Data collection was carried out at all stages of treatment: medical and nursing brigade, military mobile hospital, military medical clinical center, during rehabilitation, within 12 months of the injury.
Study: NCT06289452

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IVB102 Injection
Description: Gene transfer by intravitreal injection of the RS1 AAV vector

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IVB102 Injection
Description: Gene transfer by intravitreal injection of the RS1 AAV vector

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IVB102 Injection
Description: Gene transfer by intravitreal injection of the RS1 AAV vector
Study: NCT06198556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1167 tablets; rifampicin
Description: HRS-1167 tablets single oral dose of HRS-1167 or co-administered with rifampicin.
Study: NCT02994498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-BO1301
Description: 1, 2, or 3 capsules, three times a day, oral, at most 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-BO1301
Description: 1, 2, or 3 capsules, three times a day, oral, at most 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-BO1301
Description: 1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
Study: NCT05017532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+)
Description: The program Remédiation Cognitive de la Cognition Sociale en Schizophrénie (RC2S+) is a personalized CR treatment targeting social cognition (e.g. theory of mind, emotion recognition) using virtual reality to emulate daily social interactions
Study: NCT06035848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Association of the components of metabolic derangement and paracentesis.
Description: In the intervention group were determined:~1. Components of metabolic derangement~2. Paracentesis. Determination of surgery: 3 positive points of the components of the metabolic derangement and a positive paracentesis.~The components of the metabolic derangement are the 7 parameters described by Tepas: positive blood culture, metabolic acidosis, neutropenia, bandemia, thrombocytopenia, hyponatremia and hypotension, being considered positive when 3 or more parameters are present.~Paracentesis was considered positive according to Kosloske's criteria: obtaining more than 0.5ml of serohematic fluid, Gram-positive fluid and obtaining fecal material.~Both groups had the same pre, trans and postoperative care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bell's criteria: pneumoperitoneum
Description: In the control group, the surgery was determined according to Bell's criteria, in the presence of radiographic pneumoperitoneum as an absolute indication for surgery.
Study: NCT05717023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online guided self-help intervention for sexual distress following sexual assault
Description: 4 Sessions of guided self-help will be shared with the participants. These will be in the form of handout and video recordings that participant access through Qualtrics. The intervention is based on research on sexual trauma, psychosexual difficulties and materials developed by Bart's NHS Foundation Trust Sexual Wellbeing Service. It has been made in collaboration with clinicians within the service, experts by experience and the chief investigator.Within the document there are scripts for each session which are read out in the video recordings. The handouts depict the visual images for the video and the materials provided to participant.
Study: NCT04518033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Various commercially available face coverings
Description: Various commercially available face coverings
Study: NCT05724641

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI perfusion imaging using ASL's non-invasive technique
Description: Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI perfusion imaging using ASL's non-invasive technique
Description: Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI perfusion imaging using ASL's non-invasive technique
Description: Patients will undergo through an MRI-scan using the ASL MRI sequence, as described per protocol.
Study: NCT05101343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing meditation
Description: Daily, 5-minute breathing meditation for one week.
Study: NCT05503576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reminder mobile application
Description: After thyroidectomy, patients will be reminded of medication and control appointments. In addition, patients will be able to access up-to-date and short trainings.
Study: NCT05419791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot Asisted Gait Training with Lokomat (Endurance)
Description: * Faster application (using for Endurance) : 3 days in a week for 6 weeks,very season was 40 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot Asisted Gait Training with Lokomat (Attention and Motivation)
Description: * Smile application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Gabarello application (using for Attetion and Motivation) : 3 days in a week for 6 weeks,very season was 20 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot Asisted Gait Training with Lokomat (Activity Timing)
Description: * High Flyer application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 20 min.~* Treasures application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Curve Pursuit application (using for Activity Timing) : 3 days in a week for 6 weeks,very season was 10 min.~* Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physiotherapy
Description: -Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: -Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: -Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: -Conventional Physiotherapy : 5 days in a week for 6 weeks, every seanson was 40 min.
Study: NCT04770844

Intervention type: OTHER
Intervention: Acquisitions
Description: Three acquisitions of 1 hours during hospitalization will be realized:~* a few days after hospitalization,~* in the middle of the hospitalization,~* a few days before hospital discharge. The child will be lying on his back in a heated cradle and filmed with a specific camera. The signal will be obtained by 2k ZED 2 stereo camera in order to obtain a three-dimensional location of the child
Study: NCT04919096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-420
Description: Subjects randomised to SCB-420 arm will receive a total of 3 doses of SCB-420 as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Subjects randomised to Aflibercept arm will receive a total of 3 doses of Aflibercept as an intravitreal injection of 2 mg into the study eye every 4 weeks on Day 1, Week 4, and Week 8.
Study: NCT05875493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: 2 discrete single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: 2 discrete single doses
Study: NCT06128746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: 1 Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation
Description: Sham Hz rTMS treatment for 20 mins, follow by 30 mins intensive limb training
Study: NCT05230485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPAP level
Description: The level of continuous distending pressure (or positive end-expiratory pressure) chosen on CPAP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP level
Description: The level of continuous distending pressure (or positive end-expiratory pressure) chosen on CPAP
Study: NCT05648565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: The NEUROMARK device is an in-office, disposable bipolar RFA device with a treatment tip consisting of micro electrodes which delivers RF energy while monitoring appropriate tissue contact to maximize delivery to posterior nasal nerve and its variable branching. After topical anesthesia consisting of oxymetazoline and 1% lido followed by 4% lidocaine, the device will be placed in the posterior inferior turbinate under endoscopic visualization. The device will be activated per manufacturer's instructions
Study: NCT05370235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
Study: NCT06151743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: three cycles (toripalimab + cetuximab + platinum)
Description: Cetuximab 250 mg/m2 i.v. qw (first loading dose 400 mg/m2) for nine doses; Toripalimab 240 mg/m2 i.v. d1, q21d, three cycles; Cisplatin 25 mg/m2 i.v. d1-3, q21d, three cycles or Carboplatin AUC 5 i.v. d1, q21d, three cycles (patients with cisplatin contraindications or renal impairment after cisplatin use).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: The attending physician should select the appropriate surgical treatment and try to perform radical laryngeal preservation surgery for patients with tumor retraction after induction therapy. Patients who cannot preserve laryngeal function due to tumor load need to undergo total laryngeal resection. According to the scope of pharyngectomy, the surgical treatments include partial laryngopharyngectomy, total laryngectomy and partial pharyngectomy, total laryngopharyngectomy, and total pharyngo-laryngo-esophagectomy. Cervical lymph node dissection was performed when necessary.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy or chemoradiotherapy
Description: 1. Using intensity-modulated radiotherapy (IMRT) technology, the dose of radiotherapy is determined according to whether there are adverse prognostic factors in the postoperative pathology, including positive margins, extracapsular invasion of lymph nodes, primary pT3 or T4, N2 lymph node lesions, peripheral nerve invasion, vascular/lymphatic infiltration.~   Primary site: residual GTV or tumor bed dose 60-70Gy: 1.8-2.12 Gy / fraction. Cervical lymph nodes or lymphatic drainage area: 56-70 Gy: 1.7-2.12 Gy / fraction.~2. Postoperative adjuvant concurrent chemotherapy regimen:~Cisplatin 25mg/m2 i.v. d1-3, d22-24 or Carboplatin AUC 5 i.v. d1, d22 (if cisplatin contraindications).
Study: NCT05041920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famitinib、omeprazole
Description: famitinib malate, 25 mg on study day 1; omeprazole, 40 mg, qd on study day 10-14, 16-22; famotine malate together with omeprazole, on study day 15.
Study: NCT05503056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: art therapy
Description: six sessions of art therapy with licensed therapists

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nothing
Description: no intervention to this group
Study: NCT06025409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate 11.25 MG/ML
Description: Subcutaneous injection
Study: NCT05940818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the intensive oral care
Description: the intensive oral care
Study: NCT05906355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the wearable filtrating artificial Kidney Device
Description: the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the wearable filtrating artificial Kidney Device
Description: the wearable filtrating artificial kidney device rapidly for rapid relief of fluid overload in patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional hemodialysis machine
Description: the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional hemodialysis machine
Description: the hemodialysis machine currently used in clinical practice to reduce fluid overload in patients
Study: NCT06425185

Intervention type: OTHER
Intervention: Single-leg stance under different instability conditions
Description: Participants will perform three attempts of 20 seconds of single-leg stance on the floor and on the 7 selected configurations of the BB. The order of measurement will be randomized. The description of the chosen configurations can be found in the Detailed Description section. In all cases, the participant's objective is to ensure that the edges of the BB are not in contact with the floor.~The position of the participant on the BB will be a single-leg stance on the randomly chosen foot, with the contralateral knee slightly flexed and hands placed on the hips. Participants will look at a fixed point placed 3 meters in front of them.~A rest period of 30 seconds will be allowed between trials. The physiotherapist responsible for supervising the measurements will be the one to adjust the BB configurations when needed.
Study: NCT05818202

Intervention type: OTHER
Intervention: Questionannire
Description: The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.

Intervention type: OTHER
Intervention: Questionannire
Description: The questionannaires for both physiotherapists and stroke patients were formed in this study. The perspectives of the participants were recorded.
Study: NCT02856295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clexane (LMWH)
Description: to compare tow doses of clexane for preventing VTE in postpartum women

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clexane (LMWH)
Description: to compare tow doses of clexane for preventing VTE in postpartum women
Study: NCT06332274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Formulation : 100 mg of antibody in 10 mL of isotonic solution (25 mM citrate buffer, 15 mM L-histidine/histidine hydrochloride, 190 mM trehalose-dihydrate, and 0.02% polysorbate 20 at pH 6.5) in a single-use vial.~Dose Regimen: Tislelizumab 400 mg every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for analyses of MRD (Molecular Residual Disease)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling for analyses of MRD (Molecular Residual Disease)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling for analyses of MRD (Molecular Residual Disease)

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling for analyses of MRD (Molecular Residual Disease)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form : Solvent IV bags used for dilution of tislelizumab (for example: CHLORURE DE SODIUM FRESENIUS 0,9 %, solution injectable) Dose Regimen: every 6 weeks (Q6W) for a maximum of 9 cycles, on the first day of each cycle, in IV.
Study: NCT04305158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous Oxide
Description: Patient receiving nitrous oxide are evaluated for success of the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: Patient receiving nitrous oxide are evaluated for success of the procedure
Study: NCT04998058

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maxillary sinus floor elevation grafting with synthetic bone substitute.
Description: Bone augmentation at the floor of the maxillary sinus with bone substitutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus floor elevation grafting with synthetic bone substitute.
Description: Bone augmentation at the floor of the maxillary sinus with bone substitutes.
Study: NCT05785936

Intervention type: PROCEDURE
Intervention: Desensitization
Description: Patients that received apheresis and anti-cluster of differentiation antigen 20 for desensitization priori to kidney transplantation
Study: NCT05132777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101
Description: JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate Tablets
Description: Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).
Study: NCT05351775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application
Description: Patient is asked to do the first recording at hospital to test the device and then preferably twice daily for 1 minute period of time during the 3-month study period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bed sensor
Description: The Emfit bed sensor will be used during the index hospitalization and in home-based monitoring after hospital discharge up to 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist-worn photoplethysmography (PPG) and accelerometer data logger.
Description: Data collection with PDL is continued during initial hospitalization in the intervention group where the gold standard ECG is obtained and data can be used in algorithm development but will not be used to monitor treatment or for diagnosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch-holter ECG
Description: The patch-holter will be used during the index hospitalization and also in home if the home-based monitoring devices are signalling of a possible AF and it is not detected in the consequent ECG.
Study: NCT05613244

Intervention type: OTHER
Intervention: Phone call
Description: Patients will be asked to complete a questionnaire via a phone call
Study: NCT05007236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP7214 + Standard of care (SOC)
Description: RP7214 tablets will be administered orally twice a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Standard of care (SOC)
Description: Placebo will be administered orally twice a for 14 days
Study: NCT06000891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZP7570
Description: 13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 13 once-weekly subcutaneous injections in Part 1. 28 once-weekly subcutaneous injections in Part 2.
Study: NCT06348992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance commitment therapy and yoga
Description: The intervention used a combination of online and offline methods, based on ACT, supplemented by hatha yoga exercise intervention, the intervention group used the combination of offline ACT psychological intervention and online hatha yoga training, and the control group used mental health education, so as to explore and validate the effect of ACT combined with yoga on the improvement of parental parental burnout in children with ASD. The offline ACT psychological intervention was implemented by the researchers and psychologists, and the ACT psychological intervention was carried out once a week in community health centers or hospitals for 8 weeks. Online, a WeChat group was set up for parents with ASD, and Hatha Yoga training content and videos were sent to the group chat, and the researchers and volunteers supervised the training and clocking in and out of the group, three times a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Mental Health Education Group
Description: The control group was provided with 8 weeks of mental health education, including emotional management skills, positive coping styles, and scientific parenting methods.
Study: NCT06006676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Near Apnoeic ventilation
Description: Near Apnoeic ventilation (with a respiratory rate of 2 breaths per minute, plateau pressure of 30cmH20 and PEEP set according to the mean airway pressure being delivered during mechanical ventilation prior to randomisation) for a 72 hour period following randomisation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crossover standardised ECMO weaning trials
Description: When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crossover standardised ECMO weaning trials
Description: When all patients are eligible for a trial of ECMO weaning, they will have standardised ECMO weaning trials lasting up to 1 hour with 0 sweep gas flow. 1) One-stage weaning- sweep gas flow rate sequentially decreased to zero 2) Two-stage weaning- fraction of oxygen of sweep gas flow decreased to 0.21 sequentially. Then the sweep gas flow rate decreased to 0 sequentially